GlobeNewswire BiotechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:05:32·⚡ 决策 07-28 20:08:20 +2m48s·91.0 天前
传奇生物宣布将召开2026年二季度业绩电话会
本次仅公告二季度业绩电话会时间，未披露收入、利润、指引、CARVYKTI销售或监管进展等新增经营信息。
📄 原文GlobeNewswire Biotechnology↗ 原文
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a globa…
不做 传奇生物（LEGN.US）
仅为例行业绩电话会排期，没有业绩结果、指引变化或产品商业化新增事实，方向不明且无法形成正期望交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次仅公告二季度业绩电话会时间，未披露收入、利润、指引、CARVYKTI销售或监管进展等新增经营信息。
主要风险
- 真正可交易信息需等2026年8月11日业绩和管理层指引披露后重新研判。
原文全文
展开原文 · 1,681 字
BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results.
During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.
Investors and other interested parties may access the live audio webcast via this weblink.
A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.
ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.
INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com
PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com
During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.
Investors and other interested parties may access the live audio webcast via this weblink.
A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.
ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.
INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com
PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。